Pluristem Gains Most in 17 Months on Stem-Cell Study – Bloomberg
| Bloomberg Pluristem Therapeutics Inc. (PSTI), the Israeli developer of stem–cell therapies, rose the most in more than 17 months after an experimental treatment showed promise in a study of 20 patients with muscle injuries. The stock surged 22 percent to 16.18 … Pluristem shines in stem cell trial for muscle injuryFierceBiotech |
